Evidence map›Paper›PMID 25841171›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2015

Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease.

Shimei Ding, Wei Qu, Shuangsuo Dang, Xuan Xie, Jing Xu, Yuhuan Wang, Aiyu Jing, Chunhong Zhang, Junhong Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Review
  3. NUCB2: roles in physiology and pathology.Journal of physiology and biochemistry · 2022
    Review
  4. Article
  5. Review
  6. The Adipokine Network in Rheumatic Joint Diseases.International journal of molecular sciences · 2019
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shimei DingDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Wei QuDepartment of Nuclear Medicine, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Shuangsuo DangDepartment of Infectious Diseases, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Xuan XieDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Jing XuDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Yuhuan WangDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Aiyu JingDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Chunhong ZhangDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
Junhong WangDepartment of Endocrinology, Second Affiliated Hospital of Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNesfatin-1, recently identified as a satiety regulator, elicits an anti-atherosclerosis effect. Our study was designed to determine whether there is an association between serum nesfatin-1 and the development and severity of peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM). MATERIAL AND

methodsThis cross-sectional study included 355 T2DM patients (200 without PAD and 155 with PAD).

resultsT2DM patients with PAD exhibited marked lower serum nesfatin-1 concentrations than those without PAD. Multivariable logistic regression analysis indicated an inverse association of serum nesfatin-1 concentrations with the development of PAD in T2DM patients (OR 0.008, 95% CI 0.002 to 0.028; P<0.001). Simple linear regression analysis showed a marked correlation between serum nesfatin-1 concentrations and body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), C-reactive protein (CRP), and ankle-brachial index (ABI) in T2DM patients. By contrast, multivariable analysis showed only BMI and ABI as independent correlates of serum nesfatin-1.

conclusionsOur study shows an association of serum nesfatin-1 concentrations and the development and severity of PAD in T2DM patients.

Indexed as

Calcium-Binding ProteinsDiabetes Mellitus, Type 2DNA-Binding ProteinsFemaleHumansLogistic ModelsMaleMiddle AgedNerve Tissue ProteinsNucleobindinsPeripheral Arterial DiseaseCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNUCB2 protein, humanNucleobindins

Identifiers

PMID25841171
PMCPMC4396685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.